1
项与 64Cu-LNTH-1363S 相关的临床试验A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) in Patients with Sarcoma or Gastrointestinal Tract Cancer (PHANTOM Trial)
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) and to compare its imaging biodistribution with FAP expression by immunohistochemistry (IHC) in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).
100 项与 64Cu-LNTH-1363S 相关的临床结果
100 项与 64Cu-LNTH-1363S 相关的转化医学
100 项与 64Cu-LNTH-1363S 相关的专利(医药)
100 项与 64Cu-LNTH-1363S 相关的药物交易